← FDA DRUG APPROVALS

FDA ANDA · ANDA202716

LETROZOLE

Sponsor: CHARTWELL RX

APPLICATION
ANDA202716
TYPE
ANDA
ORIGINAL APPROVAL
2013-05-16
LATEST ACTION
2019-05-19
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued

Products

LETROZOLEDiscontinued
LETROZOLE 2.5MG · TABLET · ORAL

Approval history

2019-05-19Labeling · Supplement 2 · standardAP
2019-05-19Labeling · Supplement 3 · standardAP
2015-09-21Manufacturing (CMC) · Supplement 1 · unknownAP
2013-05-16UNKNOWN · OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →